Back to results
US 2026/0216241 A1Published application
Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
AssigneeCrispr Therapeutics AG
InventorJason Sagert
Life of this patent
Estimating the term…
Abstract
Genetically engineered T cells expressing a chimeric antigen receptor (CAR) targeting GPC3 and optionally having multiple genetic edits, including a disrupted TRAC gene, a disrupted β2M gene, a disrupted Regnase I gene, a disrupted TGFbRII gene, or a combination thereof. Also provided herein are methods of making such genetically engineered T cells and methods of using the genetically engineered T cells in cancer treatment.
Claims24
A population of genetically engineered T cells, wherein the genetically engineered T cells comprise:
- (a) a nucleic acid encoding a chimeric antigen receptor (CAR) that binds Glypican 3 (GPC3) (anti-GPC3 CAR);
- and
- (b) one or more disrupted genes, which comprise:
- (i) a disrupted T cell receptor alpha chain constant region (TRAC) gene,
- (ii) a disrupted beta-2 microglobulin (β2M) gene,
- (iii) a disrupted transforming growth factor beta receptor II (TGFbRII) gene,
- (iv) a disrupted Regnase-1 (Reg1) gene,
- (v) a disrupted Casitas B-Lineage Lymphoma Proto-Oncogene-B (CBLB) gene, or
- (vi) a combination of any one of (i)-(v).
6 more elements
-16. (canceled)
-41. (canceled)
-48. (canceled)
-54. (canceled)
Dependencies are inferred from the claim text.